Bio

Bio


Dr. Christopher Shen serves as the Executive Director (US) of Singapore-Stanford Biodesign and is also a Consulting Associate Professor of Medicine at Stanford University.

Dr. Shen is also the Managing Director of Vertex Healthcare - part of a global venture fund network under the auspices of Vertex Venture Holdings, a member of Temasek Holdings. Dr. Shen has over 15 years of healthcare investing experience. Prior to joining Vertex, Chris led numerous medtech and biopharma investments at New Enterprise Associates and Essex Woodlands. He worked with seven companies that have since gone public or been successfully acquired, worth over US$1.5 billion in value. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology. Previously, Dr. Shen worked in operating roles at Guidant and Pfizer.

Academic Appointments


  • Consulting Associate Professor, Surgery

Administrative Appointments


  • Executive Director, Singapore Stanford Biodesign (2010 - Present)

Boards, Advisory Committees, Professional Organizations


  • Board Member, Kona Medical (2014 - Present)
  • Board Member, Ivantis (2015 - Present)
  • Board Member, Moximed (2014 - Present)

Professional Education


  • MD, Stanford University, School of Medicine
  • MBA, Stanford University, Graduate School of Business
  • MS, Stanford University, Biomechanical Engineering
  • BS, Stanford University, Biological Science

Research & Scholarship

Current Research and Scholarly Interests


Healthcare innovation. Global medical technology assessment/needs finding. Value-driven innovation. Asia-pacific region. Medical technology development, financing, operations, regulatory, reimbursement.

Publications

All Publications


  • Outcomes from a Postgraduate Biomedical Technology Innovation Training Program: The First 12 Years of Stanford Biodesign ANNALS OF BIOMEDICAL ENGINEERING Brinton, T. J., Kurihara, C. Q., Camarillo, D. B., Pietzsch, J. B., Gorodsky, J., Zenios, S. A., Doshi, R., Shen, C., Kumar, U. N., Mairal, A., Watkins, J., Popp, R. L., Wang, P. J., Makower, J., Krummel, T. M., Yock, P. G. 2013; 41 (9): 1803-1810

    Abstract

    The Stanford Biodesign Program began in 2001 with a mission of helping to train leaders in biomedical technology innovation. A key feature of the program is a full-time postgraduate fellowship where multidisciplinary teams undergo a process of sourcing clinical needs, inventing solutions and planning for implementation of a business strategy. The program places a priority on needs identification, a formal process of selecting, researching and characterizing needs before beginning the process of inventing. Fellows and students from the program have gone on to careers that emphasize technology innovation across industry and academia. Biodesign trainees have started 26 companies within the program that have raised over $200 million and led to the creation of over 500 new jobs. More importantly, although most of these technologies are still at a very early stage, several projects have received regulatory approval and so far more than 150,000 patients have been treated by technologies invented by our trainees. This paper reviews the initial outcomes of the program and discusses lessons learned and future directions in terms of training priorities.

    View details for DOI 10.1007/s10439-013-0761-2

    View details for Web of Science ID 000323736800002

    View details for PubMedID 23404074

Footer Links:

Stanford Medicine Resources: